Compare REBN & BFRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REBN | BFRG |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Restaurants | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.8M |
| IPO Year | 2017 | N/A |
| Metric | REBN | BFRG |
|---|---|---|
| Price | $1.40 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.2K | ★ 158.1K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,094,628.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.54 | N/A |
| 52 Week Low | $1.36 | $0.43 |
| 52 Week High | $3.40 | $2.04 |
| Indicator | REBN | BFRG |
|---|---|---|
| Relative Strength Index (RSI) | 36.42 | 44.97 |
| Support Level | N/A | $0.59 |
| Resistance Level | $2.00 | $0.72 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 37.31 |
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.